ALISON WATKINS: Open Payments
NPI 1336319482 · CHEYENNE, WY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$995 in 51 payments from 11 companies in 2025. Trend: 2023 $988 · 2024 $902 · 2025 $995
Food & beverage: $989Education: $7
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 17 | $427 |
| Regeneron Healthcare Solutions, Inc. | 16 | $200 |
| Novartis Pharmaceuticals Corporation | 4 | $83 |
| GENZYME CORPORATION | 3 | $79 |
| Genentech USA, Inc. | 3 | $55 |
| GlaxoSmithKline, LLC. | 3 | $55 |
| Lilly USA, LLC | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| CSL Behring | 1 | $16 |
| PFIZER INC. | 1 | $14 |
Products named: DUPIXENT, BREZTRI, FASENRA, Xolair, AIRSUPRA, TEZSPIRE, TRELEGY ELLIPTA, EBGLYSS.
Industry payments across WY — which companies pay providers there.
